Roche presents vamikibart data. Roche Holding stock is valued at CHF 326.6 billion

Published on 10/15/2026 at 10:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche's Phase III success exceeded 80 percent in 2026, versus 65 percent in 2025. Roche Holding stock costs EUR 401.13 on October 15, 2026.

Pipeline metrics and trading value

Roche presented one-year vamikibart data on October 11, 2026.
Phase III success exceeded 80 percent in 2026, compared with 65 percent in 2025.
Roche Holding stock was trading at EUR 401.13 at 10:31 a.m. CEST on October 15, 2026, while its market value was CHF 326.6 billion.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding (ISIN CH1499059983) had a market value of CHF 326.6 billion as of October 15, 2026, while its euro quote stood at EUR 401.13. The latest company-specific development was Roche's presentation of new one-year Phase III data for vamikibart on October 11, 2026, according to FinanzNachrichten.

Roche advances its pipeline

The vamikibart update adds another clinical milestone to Roche's development pipeline. The source describes one-year Phase III data for the treatment candidate in uveitic macular edema, a serious cause of vision loss, but does not provide a headline efficacy percentage in the cited release.

Roche's broader research message was quantified at its September 28, 2026 Pharma Day. Novapharma News reported that the company's Phase III success rate exceeded 80 percent in 2026 year to date, compared with 65 percent in 2025.

What does 80 percent mean?

The comparison points to a higher proportion of late-stage programs meeting their development objectives. It does not remove the commercial risk around regulatory decisions, launch timing or the competitive position of individual medicines. For investors, the useful signal is the change from 65 percent to more than 80 percent, rather than the vamikibart data in isolation.

Dates for the next update

Roche's next scheduled company event is its third-quarter sales presentation on October 22, 2026, at 2:00 p.m. CEST. The invitation from Roche says the sales release will be published before the Swiss exchange opens that day. Roche also lists a Berenberg Pharma CFO Series event for November 2, 2026, at 3:00 p.m. CET on its investor page.

Stock value and trading view

Roche Holding's primary listing is on SIX, where the structured quote showed CHF 382.40 on October 15, 2026. The same quote placed the 52-week range at CHF 236.00 to CHF 383.00, leaving the latest Swiss price below the upper end of that range.

Roche Holding stock was trading at EUR 401.13 at Lang & Schwarz on October 15, 2026 at 10:31 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.